Treatment Pattern and Overall Survival in Newly Diagnosed Multiple Myeloma Patients who are not Eligible for Autologous Stem Cell Transplantation

被引：0

作者：

He, Jianming ^{[1
]}

Qiu, Lugui ^{[2
]}

Schmerold, Luke ^{[3
]}

Potluri, Ravi ^{[3
]}

Li, Lin ^{[4
]}

Hu, Peter ^{[5
]}

Nemat, Sepideh ^{[6
]}

Smugar, Steven S. ^{[7
]}

Appiani, Carlos ^{[8
]}

Mehra, Maneesha ^{[9
]}

Richarz, Ute ^{[10
]}

机构：

[1] Janssen, Raritan, NJ USA

[2] Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China

[3] Smart Analyst, New York, NY USA

[4] Xian Janssen Pharmaceut Ltd, Beijing, Peoples R China

[5] Janssen R&D, Raritan, NJ USA

[6] Janssen R&D, High Wycombe, Bucks, England

[7] Janssen R&D, Titusville, NJ USA

[8] Janssen R&D, Spring House, PA USA

[9] Janssen Global Serv, Raritan, NJ USA

[10] Janssen Global Serv, Zug, Switzerland

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

Multiple myeloma; multiple myeloma-specific survival; multiple-myeloma specific survival;

D O I：

10.1016/j.clml.2019.09.380

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SP-054

引用

页码：E229 / E229

页数：1

共 50 条

[31] Clinical Outcomes of Newly Diagnosed Multiple Myeloma Patients with Elevated Lactate Dehydrogenase Who Underwent Autologous Hematopoietic Stem Cell Transplantation
Bal, Susan
Choi, Kwangmin
Landau, Heather J.
Starczynowski, Daniel T.
Girnius, Saulius K.
BLOOD, 2018, 132
[32] ANALYSIS OF THE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY PATIENTS (65 YEARS OLD) WITH MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION.
Cejalvo, M. J.
Rubio, L.
Romero, S.
Legarda, M.
Jimenez, M.
Perla, A.
Jarque, I
Ribas, P.
Arnao, M.
Andreu, R.
Dominguez, E.
De la Rubia, J.
HAEMATOLOGICA, 2018, 103 : 22 - 23
[33] The Determination Trial Impact on Upfront (vs Delayed) Autologous Stem Cell Transplantation for Transplant-Eligible Newly Diagnosed Multiple Myeloma
Dulka, Brooke
Bone, Robert N.
Jeune-Smith, Yolaine
Baljevic, Muhamed
Feinberg, Bruce A.
BLOOD, 2022, 140 : 10958 - 10959
[34] Lenalidomide: A Review of Its Continuous Use in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem-Cell Transplantation
Paul L. McCormack
Drugs & Aging, 2015, 32 : 409 - 418
[35] Lenalidomide: A Review of Its Continuous Use in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem-Cell Transplantation
McCormack, Paul L.
DRUGS & AGING, 2015, 32 (05) : 409 - 418
[36] Tailoring Initial Treatment for Newly Diagnosed, Transplantation-Eligible Multiple Myeloma
Stadtmauer, Edward A.
ONCOLOGY-NEW YORK, 2010, 24 (03): : 7 - 13
[37] Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma
James A. Davis
Aswani Thurlapati
Erin Weeda
Kelly J. Gaffney
Deidra Smith
Andy Maldonado
Katelynn Granger
Kristy E. Martin
Yolanda M. Williams
Taylor Herrington
Arash Velayati
Jonathan K. Bakos
Kimberly Green
Hamza Hashmi
Annals of Hematology, 2024, 103 : 251 - 258
[38] Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma
Davis, James A.
Thurlapati, Aswani
Weeda, Erin
Gaffney, Kelly J.
Smith, Deidra
Maldonado, Andy
Granger, Katelynn
Martin, Kristy E.
Williams, Yolanda M.
Herrington, Taylor
Velayati, Arash
Bakos, Jonathan K.
Green, Kimberly
Hashmi, Hamza
ANNALS OF HEMATOLOGY, 2024, 103 (01) : 251 - 258
[39] Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study
Garderet, Laurent
Beohou, Eric
Caillot, Denis
Stoppa, Anne Marie
Touzeau, Cyrille
Chretien, Marie Lorraine
Karlin, Lionel
Moreau, Philippe
Fontan, Jean
Blaise, Didier
Polge, Emmanuelle
Gueye, Mor Seny
Ikhlef, Souhila
Marjanovic, Zora
Labopin, Myriam
Mohty, Mohamad
HAEMATOLOGICA, 2016, 101 (11) : 1390 - 1397
[40] Treatment of transplant-eligible patients with newly diagnosed multiple myeloma
Nakaseko, Chiaki
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →